ABBV AbbVie Inc. - Fundamental Analysis

AbbVie trades at a premium valuation with strong historical profitability and cash flow generation, but faces significant near-term headwinds including a collapsing earnings base, elevated payout ratio, and weakening insider sentiment. While the stock has delivered impressive price performance over the past five years (+187.1%), recent quarterly earnings have been volatile, with two of the last four misses exceeding -55% in surprise. The company's P/E of 176x and negative Price/Book reflect structural challenges post-divestiture and high leverage, offsetting its attractive 2.98% dividend yield and robust operating margins. Relative to peers like MRK and ABT, AbbVie appears overvalued on earnings despite stronger revenue growth (9.1% vs sector avg 11.82%), though forward P/E of 19.16 suggests some normalization ahead.